Spark Therapeutics Announces Cowen Healthcare Conference Participation

PHILADELPHIA, March 02, 2016 -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that Jeffrey D. Marrazzo, co-founder and chief executive officer, is presenting at the Cowen 36^th Annual Health Care Conference on Monday, March 7, 2016 at 4:40 pm (EST), at the Marriott Copley Place, Boston, Massachusetts. 

To access the slide deck presented, please visit the "Investor Presentations" section of the Spark Therapeutics website at www.sparktx.com. 

About Spark Therapeutics
Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark’s most advanced product candidate, SPK-RPE65 (voretigene neparvovec), which has received both breakthrough therapy and orphan product designation, recently reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark builds on two decades of research, development and manufacturing at The Children’s Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com.

Contacts

Investor Relations
Spark Therapeutics, Inc.
Stephen W. Webster
Chief Financial Officer
(855) SPARKTX (1-855-772-7589)

Media
Ten Bridge Communications
Dan Quinn
(781) 475-7974
[email protected]